Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · IEX Real-Time Price · USD
1.210
-0.010 (-0.82%)
At close: Jul 19, 2024, 4:00 PM
1.330
+0.120 (9.92%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Gain Therapeutics Stock Forecast
GANX's stock price has decreased by -72.5% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 8.25, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 581.82% from the current stock price of 1.21.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for GANX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +561.16% | Jul 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +561.16% | Jul 2, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +643.80% | May 31, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +643.80% | May 28, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +643.80% | May 15, 2024 |
Financial Forecast
Revenue This Year
612.00K
from 55.18K
Increased by 1,009.10%
Revenue Next Year
357.00K
from 612.00K
Decreased by -41.67%
EPS This Year
-0.99
from -1.71
EPS Next Year
-1.05
from -0.99
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 1.1M | 420,000 | 236,250 | 236,250 | 105.3M |
Avg | 612,000 | 357,000 | 114,750 | 114,750 | 51.1M |
Low | 98,000 | 294,000 | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 1,802.9% | -31.4% | -33.8% | 105.9% | 91,673.4% |
Avg | 1,009.1% | -41.7% | -67.9% | - | 44,474.3% |
Low | 77.6% | -52.0% | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.97 | -0.89 | -1.75 | -1.98 | 1.29 |
Avg | -0.99 | -1.05 | -1.70 | -1.93 | 1.25 |
Low | -1.05 | -1.23 | -1.64 | -1.85 | 1.21 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.